Kymera Therapeutics (KYMR) Interest Coverage Ratio (2019 - 2026)
Kymera Therapeutics (KYMR) reported Interest Coverage Ratio of 1379.57 for Q1 2026, down 33.46% year-over-year from 2073.32 in Q1 2025, and down 26.83% quarter-over-quarter from 1087.73 in Q4 2025.
Kymera Therapeutics (KYMR) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of Interest Coverage Ratio data on file, last reported at 1379.57 in Q1 2026.
- Interest Coverage Ratio for Q1 2026 came in at 1379.57, down 33.46% year-over-year; the trailing twelve-month figure through Mar 2026 was 1005.96 (up 8.89% YoY), and the FY2025 annual result was 944.32, up 10.13% from the prior year.
- Interest Coverage Ratio slipped to 1379.57 in Q1 2026 per KYMR's latest filing, from 1087.73 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 371.38 in Q4 2023 and troughed at 1402.66 in Q3 2023.
- A 5-year average of 986.55 and a median of 944.09 in 2025 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio jumped 43.28% in 2023, then plunged 268.55% in 2024.
- A 5-year view of Interest Coverage Ratio shows it stood at 654.75 in 2022, then jumped by 43.28% to 371.38 in 2023, then sank by 268.55% to 1368.73 in 2024, then increased by 20.53% to 1087.73 in 2025, then retreated by 26.83% to 1379.57 in 2026.
- Business Quant data shows KYMR's Interest Coverage Ratio at 1379.57 in Q1 2026, 1087.73 in Q4 2025, and 944.09 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | -1,379.57 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,379.57 |
| Dec 31, 2025 | -1,087.73 |
| Sep 30, 2025 | -944.09 |
| Jun 30, 2025 | -782.94 |
| Mar 31, 2025 | -1,033.69 |
| Dec 31, 2024 | -1,368.73 |
| Sep 30, 2024 | -1,202.07 |
| Jun 30, 2024 | -834.84 |
| Mar 31, 2024 | -838.13 |
| Dec 31, 2023 | -371.38 |
| Sep 30, 2023 | -1,402.66 |
| Jun 30, 2023 | -903.81 |
| Mar 31, 2023 | -824.11 |
| Dec 31, 2022 | -654.75 |
| Sep 30, 2022 | -1,246.72 |
| Jun 30, 2022 | -995.37 |
| Mar 31, 2022 | -900.80 |
| Dec 31, 2021 | -666.55 |
| Sep 30, 2021 | -409.10 |
| Jun 30, 2021 | -883.21 |